1. | Carone G., Schwierz Ch., Xavier A. (2012). Cost-containment policies in public pharmaceutical spending in the EU. Economic Papers, 461. |
2. | Cutler M.D., Everett W. (2010). Thinking outside the pillbox – medication adherence as a priority for health care reform. The New England Journal of Medicine, 362 (17), 1553–1055. |
3. | Enterprice and Industry. Pobrano z: http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/structimpact_pharmaprices_032011_en.pdf. |
4. | Eurostat database. Pobrano z: http://ec.europa.eu/eurostat/data/database. |
5. | Henry D., Lexchin J. (2002). The pharmaceutical industry as a medicines provider. The Lancet, 360 (9345), 1590–1595. |
6. | IMS (2013). Global Pharmaceuticals. Marketing Channel Reference. Pobrano z: http://raport2014.pelion.eu/pl. |
7. | Kanavos P., Schurer W., Vogler S. (2011). The Pharmaceutical Distribution Chain in the European Union: Structure and Impact on Pharmaceutical Prices’. Emint. Final report. |
8. | Leopold Ch., Mantel-Teeuwisse A.K., Vogler S., Valkova S., de Joncheere K., Leufkens H.G.M., Wagner A.K., Ross-Degnan D., Laing R. (2014). Effect of the economic recession on pharmaceutical policy and medicine sales in eight European countries. Bulletin of the World Health Organization, 92 (9), 630–640D. |
9. | OECD (2008). Pharmaceutical Pricing Policies in a Global Market. OECD Health Policy Studies. OECD.Stat. Pobrano z: stats.oecd.org (12.04.2016). |
10. | PMR (2015). Rynek produktów OTC w Polsce 2015. Prognozy rozwoju na lata 2015–2020. Pobrano z: http://forumfarmaceutyczne.blog.pl/2015/08/20/w-2015-roku-rynek-produktow-otc-w-polsce-powroci-na-sciezke-wzrostu. |
11. | Puig-Junoy J., García-Gómez P., Casado-Marín D. (2011). Free Medicines thanks to Retirement: Moral Hazard and Hospitalization Offsets in an NHS. Tinbergen Institute Discussion Paper, 108 (3), 1–33. |
12. | Ustawa z dnia 12 maja 2011 r. o refundacji leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych. Dz.U. 2011, nr 122n poz. 696 z późn. zm. |
13. | Vogler S., Habimana K. (2014). Pharmaceutical pricing policies in European countries. Vienna: Gesundheit Österreich Forschungs- und Planungs GmbH. |
14. | Vogler S., Habl C., Leopold C., Rosian-Schikuta I., de Joncheere K., Lyager T.T. (2008). Pharmaceutical Pricing and Reimbursement Information. PPRI Report. Vienna: ÖBIG. |
15. | Vogler S., Österle A., Mayer S. (2015). Inequalities in medicine use in Central Eastern Europe: an empirical investigation of socioeconomic determinants in eight countries. International Journal for Equity in Health, 14 (124), 1–19. |
16. | Vogler S., Zimmermann N., Leopold C., Joncheere K.D. (2011). Pharmaceutical policies in European countries in response to the global financial crisis. Southern Medical Review, 4 (2), 69–79. |
17. | Xu K., Evans D.B., Carrin G., Aguilar-Rivera A.M. (2005). Designing health financing systems to reduce catastrophic health expenditure. Technical Brief For Policy-Makers, 2. |
18. | Zuidberg C. (2010). The pharmaceutical system of the Netherland. Vienna. |